DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for ovarian adenocarcinoma — screening already-approved drugs against its 29-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian adenocarcinoma maps to a 29-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
One hundred and eleven women with FIGO Stages III and IV ovarian adenocarcinoma were treated with melphalan as first chemotherapy. The overall response rate was 19.8%, with 10.8% achieving a complete response. Women who had not received prior radiation therapy had a statistically significant better response. Median survival was statistically significantly improved only in those who achieved a complete response compared to those with a partial response, no change, or progression. The authors concluded that maximal surgery and combination chemotherapy were needed to improve on these results.
Two review articles from 2017 note that epithelial ovarian cancers are the most common ovarian malignancies and are usually advanced when diagnosed in more than two thirds of patients because they remain asymptomatic until metastasis. These cancers have the highest mortality rate among female reproductive system malignancies. The reviews state that the incidence of different kinds of ovarian cancer has not received due attention and that they remain challenging issues.
No drug other than melphalan is mentioned in these abstracts. The 1978 study is small by modern standards and the response rate is low. The 2017 reviews provide no new treatment data. What is still missing is any evidence from a properly powered, randomised trial that tests a repurposed drug specifically against ovarian adenocarcinoma, with clear patient stratification by prior treatment and tumour genetics, and with funding adequate to follow survival endpoints rather than just response rates.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics and Gynecology · 1978 · 22 citations
Melphalan Chemotherapy in Advanced Ovarian Carcinoma
AbstractOne hundred and eleven consecutive women with FIGO Stages III and IV ovarian adenocarcinoma were treated with melphalan as their initial chemotherapy. The response rate was 19.8% with 10.8% having a complete response. There was a statistically significant improvement in response in those women with no prior radiation therapy. Moreover, there was a statistically significant improvement in median survival in those patients achieving a complete response to melphalan as compared to those with a partial response, with no change or progression of their malignancy. A review of the results of maximal surgery and combination chemotherapy is presented as a plan of therapy to improve upon the results of melphalan chemotherapy in women with advanced ovarian carcinoma.
Zenodo (CERN European Organization for Nuclear Research) · 2017 · 0 citations · open access
Ovarian Adenocarcinoma - A Review Article
AbstractIntroduction: Among all the female reproductive system cancer, ovarian malignancies have been allocated most of the clinical studies. Since they usually remain asymptomatic until metastasis, epithelial ovarian cancers are the most common ovarian malignancies that are advance when diagnosed in more than two thirds of the patients. Methods: In this review article, the databases Medline, Cochrane, Science Direct, and Google Scholar were thoroughly searched to identify the Ovarian Adenocarcinoma. In this review, the papers published until early January 2017 that were conducted to study the Ovarian Adenocarcinoma were selected. Results: The ovary is in the form of two small glands on both sides of uterus that is covered by the end of ovarian tube. Ovarian epithelial cancers are the most common cancers that remain asymptomatic until metastasis; they have the highest rate of mortality among all kinds of malignancies of female reproductive system. Discussion and conclusion: The incidence of different kinds of ovarian cancer are included among the cases that have not been given due attention so far. However, they have turned out to be challenging issues. Ovary adenocarcinoma cervicitis constitutes Key words: Ovarian, Adenocarcinoma
Zenodo (CERN European Organization for Nuclear Research) · 2017 · 0 citations · open access
Ovarian Adenocarcinoma - A Review Article
AbstractIntroduction: Among all the female reproductive system cancer, ovarian malignancies have been allocated most of the clinical studies. Since they usually remain asymptomatic until metastasis, epithelial ovarian cancers are the most common ovarian malignancies that are advance when diagnosed in more than two thirds of the patients. Methods: In this review article, the databases Medline, Cochrane, Science Direct, and Google Scholar were thoroughly searched to identify the Ovarian Adenocarcinoma. In this review, the papers published until early January 2017 that were conducted to study the Ovarian Adenocarcinoma were selected. Results: The ovary is in the form of two small glands on both sides of uterus that is covered by the end of ovarian tube. Ovarian epithelial cancers are the most common cancers that remain asymptomatic until metastasis; they have the highest rate of mortality among all kinds of malignancies of female reproductive system. Discussion and conclusion: The incidence of different kinds of ovarian cancer are included among the cases that have not been given due attention so far. However, they have turned out to be challenging issues. Ovary adenocarcinoma cervicitis constitutes Key words: Ovarian, Adenocarcinoma
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
